Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial ResultsBusiness Wire • 04/01/24
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024Business Wire • 03/27/24
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic MicroangiopathyBusiness Wire • 02/20/24
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare TrustBusiness Wire • 02/01/24
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023Business Wire • 11/06/23
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic MicroangiopathyBusiness Wire • 11/03/23
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA NephropathyBusiness Wire • 10/16/23
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023Business Wire • 08/04/23
Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association CongressBusiness Wire • 06/12/23